114 results on '"Wasserman, Todd"'
Search Results
2. The Clinical Pharmacology of Misonidazole in Radiation Therapy Oncology Group Trials
3. Chemical modifiers of radiation and chemotherapy: tumor sensitization and normal tissue protection
4. The Design of Clinical Trials and Clinical Toxicology of the Nitroimidazole Misonidazole in Phase I Testing in the Radiation Therapy Oncology Group
5. Misonidazole Clinical Trials in the United States Radiation Therapy Oncology Group (RTOG)
6. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801
7. Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non–Small-Cell Lung Cancer: An Analysis of RTOG 9801
8. The Growth of Academic Radiation Oncology: A Survey of Endowed Professorships in Radiation Oncology
9. Mentors, Mensches, and Models
10. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
11. Clinically Meaningful Differences in Patient-Reported Outcomes With Amifostine in Combination With Chemoradiation for Locally Advanced Non–Small-Cell Lung Cancer: An Analysis of RTOG 9801
12. Balancing on a Knife's Edge: Evidence-Based Medicine and the Marketing of Health Technology
13. Celebrating 40 Years of Clinical Inquiry: The RTOG'S Ruby Anniversary
14. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial
15. In Reply
16. Randomized Trial of Amifostine in Locally Advanced Non–Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01
17. Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)
18. A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers
19. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma
20. Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease
21. Letter to the Editor
22. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases
23. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04
24. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer
25. Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer
26. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison
27. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
28. Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized hodgkin disease and unfavorable prognostic features
29. Irradiation with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: final results of RTOG 80-05
30. Physician resource utilization in radiation oncology: A model based on management of carcinoma of the prostate
31. Survival and prognostic factors of non-small cell lung cancer (NSCLC) patients treated with definitive three-dimensional (3D) radiation therapy
32. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemo-radiation studies
33. Cost benefit of emerging technology in localized carcinoma of the prostate
34. When is a negative study not negative?
35. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique
36. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials
37. Quality of life: The patient's endpoint
38. Clinical introduction of a commercial treatment chair to facilitate thorax irradiation
39. End of an era or not? That is the question—In response to Dr. J. M. Brown, IJROBP 32:883–885; 1995
40. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
41. Overview of late effects normal tissues (LENT) scoring system
42. Joint statement of mission by the RTOG/EORTC working groups
43. Pathophysiology of irradiated skin and breast
44. Overview: Late effects of normal tissues (LENT) scoring system
45. The impact on quality of life by radiation late effects
46. 132 Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials
47. Assurance of high quality linac-based stereotactic radiosurgery
48. Editors' note
49. Editors' note
50. Radiation therapy for stage i and iia testicular seminoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.